temanogrel

Temanogrel is an orally bioavailable small molecule that acts as a selective inverse agonist of the serotonin 2A receptor (5-HT2A). By binding to and inhibiting the 5-HT2A receptor on platelets and vascular smooth muscle cells, it reduces serotonin-mediated platelet aggregation and vasoconstriction. This mechanism may attenuate thrombosis risk and improve blood flow in cardiovascular conditions. Temanogrel was originally developed by Arena Pharmaceuticals and later by Pfizer following acquisition. Its primary indications have included Raynaud's phenomenon/systemic sclerosis-related Raynaud's disease and myocardial ischemia; development for acute coronary syndromes has been discontinued[1][2][3][7][8].

Other names

Temanogrel HCl957466-27-2UNII-5QEY8NZP3TUNII5QEY8NZP3TUNII 5QEY8NZP3T